Generation of universal natural killer cells from a cryopreserved cord blood mononuclear cell‐derived induced pluripotent stem cell library

Natural killer (NK) cells play a key role in innate immunity and are regarded as a promising candidate for cellular immunotherapy. Natural killer cells may be generated from different sources, including induced pluripotent stem cells (iPSCs); these stem cells produce an abundant amount of NK cells to meet the needs of a wide range of clinical applications. Autologous iPSCs are expensive and labor‐intensive to prepare, while allogeneic iPSCs require human leukocyte antigen (HLA) matched cells to avoid the risk of immune rejection. In the current study, we prepared HLA‐matched iPSCs using HLA common haplotype homozygous (HLAh) donors from cryopreserved human cord blood (CB) sourced from the Tianjin Cord Blood Public Bank. This approach was designed to generate a CB‐derived iPSC library from HLAh donors and use it to produce off‐the‐shelf NK cells. Starting with readily available cryopreserved CB mononuclear cells (cryoCBMCs), we produced cryoCBMC‐derived iPSCs (cryoCB‐iPSCs). These cryoCB‐iPSCs were induced to generate embryoid bodies (EBs) using an improved 3D suspension culture method, and induced NK (iNK) cells were differentiated from EBs. iNK cells expressed specific surface markers of NK cells, exhibited cytotoxicity comparable with NK cells generated from CB (CB‐NK) and peripheral blood (PB‐NK), and expressed lower levels of KIRs and HLA‐DR compared to CB‐NK and PB‐NK. Taken together, we have shown that an iPSC library can be established from HLAh cryoCBMCs, and cryoCB‐iPSCs can be used to generate a large number of ‘universal’ NK cells for future clinical applications. Natural killer (NK) cells are a key component of innate immunity as well as adaptive immune cell therapies. Induced pluripotent stem cells (iPSCs) offer an unlimited source for NK derivation. This study shows that an iPSC library can be established from HLA common haplotype homozygous (HLAh) cryopreserved cord blood (cryoCB), and cryoCB‐iPSCs can be used to generate a large number of ‘universal’ iNK cells for future clinical applications.